Jordana Joy, Associate Editor

Cleveland, Ohio’s Great Lakes Science Center Community Engagement Coordinator JonDarr Bradshaw details what those in the path of totality should expect, as well as the science center’s initiatives to keep eyes healthy during the event.

Catch up on what happened in optometry during the week of March 18-March 22.

Peer and public reviews for Care of the Patient with Primary Open-Angle Glaucoma will be taken until April 24.

Multiple symptomatic improvements, as well as tear film break-up time improvements and a reduction in ocular pain, were noted.

With The Ohio State University College of Optometry in the path of totality for this year's total solar eclipse, 1 optometry school has prepared its alumni, students, and doctors to share information with the public.

Nicholas Gilberg, OD, with EssilorLuxxotica's Leonardo team walks through the basics of the education software that can be implemented in any practice.

Sandra Block, OD, M Ed, MPH, FAAO, FCOVD, said in a recent statement that global eye care has come a long way thanks to eye care providers.

Laura Periman, MD, talks through what was gained from the conference, from becoming acquainted with new technological advancements to renewing passion for dry eye care.

The newest technology, fashion trends, and business developments that were featured at this year’s show.

Scott Moscow, OD, talks his practice's contact lens "test-driving" option and how to get patients on board with trying out new corrective eyewear.

Catch up on what happened in optometry during the week of March 11-March 15.

Alysse Henkel, vice president of research and inSights at The Vision Council, details recent research conducted by the company regarding consumer purchasing habits and trends.

Report findings show that patient interest in contact lenses can be dissuaded by lack of recommendations by eye care providers.

Prevent Blindness and the American Optometric Association have released resources and educational information to help the public and eye care providers prepare for the astronomical event on April 8.

Dr Brianna Rhue, OD, FAAO, FSLS details her upcoming presentation "Cutting Out Surgery for the Management of Refractive Error," where she will detail the underutilization of orthokeratology during Vision Expo East 2024 later this week.

The new Focused inSights report tracks trends in eyeglasses frames preferences, with factors such as sustainability, technology, and online versus in-person shopping impacting purchasing habits.

This year’s conference, held from March 14-17, will be its last in New York City.

The online eyewear retailer has partnered with Meta, US Vision, and PPG through its new Zenni Business platform.

The lens technology was found to have improved headache symptoms.

Catch up on what happened in optometry during the week of March 4-March 8.

Horace Deal, OD, will serve a 2024-2025 term and brings nearly 30 years of optometric experience to the position.

The Vision Council's CEO Ashley Mills previews a nostalgic year for Vision Expo East, as it celebrates and looks back on almost 40 years in New York.

Marc R Bloomenstein, OD, FAAO, chats with Optometry Times on the benefits of using Vevye to treat dry eye disease, when to prescribe, and how to distinguish quality candidates.

Eric Fazio, OD, sits down with Optometry Times to weigh the pros and cons of EVO ICLs and LASIK and the role comanagement plays in the decision.

The new prescription lens series, which transition faster while keeping out UVA and UVB rays, will be available in April 2024.

Catch up on what happened in optometry during the week of February 26-March 1.

Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.

R Tracy Williams, OD, FAAO, reflects on his favorite stories working as a team optometrist for the Chicago Bulls and Chicago White Sox in the last 20 years.

A treatment option for thyroid eye disease may be on its way to finalization in China with the positive endpoint results from a Phase 3 clinical trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody.